daratumumab
navigate by keyword : wright undefined teachingslide promyelocytes paraprotein oncology myeloma multiple monoclonal microscopicdiagnosis microscope medicinelaboratory medication medicaleducation medical marrow lenalidomide laboratory hematopathology hematology granulation gammapathy daratumumab cytology clinicalpathology clinical chemotherapy cells cd38 cancer bortezomid bone binucleation binucleated anticancer antibody

Abnormal promyelocytes secondary to treatment with Daratumumab. Royalty Free Stock Photo
Abnormal promyelocytes secondary to treatment with Daratumumab. Royalty Free Stock Photo
Abnormal promyelocytes secondary to treatment with Daratumumab. Royalty Free Stock Photo
CD38 (ectodomain fragment) enzyme. Target of the monoclonal antibody drug daratumumab, used for the treatment of multiple myeloma Royalty Free Stock Photo
Abnormal promyelocytes secondary to treatment with Daratumumab. Royalty Free Stock Photo
CD38 (ectodomain fragment) enzyme. Target of the monoclonal antibody drug daratumumab, used for the treatment of multiple myeloma Royalty Free Stock Photo
CD38 (ectodomain fragment) enzyme. Target of the monoclonal antibody drug daratumumab, used for the treatment of multiple myeloma Royalty Free Stock Photo
Abnormal promyelocytes secondary to treatment with Daratumumab.
Abnormal promyelocytes secondary to treatment with Daratumumab. Royalty Free Stock Photo
Abnormal promyelocytes secondary to treatment with Daratumumab. Royalty Free Stock Photo
CD38 (ectodomain fragment) enzyme. Target of the monoclonal antibody drug daratumumab, used for the treatment of multiple myeloma Royalty Free Stock Photo
CD38 (ectodomain fragment) enzyme. Target of the monoclonal antibody drug daratumumab, used for the treatment of multiple myeloma Royalty Free Stock Photo
Daratumumab monoclonal antibody drug. Targets CD38, indicated for treatment of multiple myeloma. Generic name and stylized Royalty Free Stock Photo
CD38 (ectodomain fragment) enzyme. Target of the monoclonal antibody drug daratumumab, used for the treatment of multiple myeloma Royalty Free Stock Photo
Abnormal promyelocytes secondary to treatment with Daratumumab. Royalty Free Stock Photo
Daratumumab is an anti-cancer monoclonal antibody medication that binds to CD38 which is overexpressed in multiple myeloma cells. It induces alterations in bone marrow promyelocytes such as binucleation, abnormal granulation, etc. Bone marrow, Wright x1000,

Stockphotos.ro (c) 2026. All stock photos are provided by Dreamstime and are copyrighted by their respective owners.